62.49
+0.01(+0.02%)
Currency In USD
Address
, DE
United States of America
Phone
N/A
Website
N/A
Sector
Healthcare
Industry
Biotechnology
Employees
88
First IPO Date
September 15, 2023
| Name | Title | Pay | Year Born |
| Dr. Kenneth Song M.D. | President, Chief Executive Officer & Director | 646,000 | 1975 |
| Dr. Susan Moran M.D. | Chief Medical Officer | 559,840 | 1969 |
| Mr. Arvind Kush | Chief Financial Officer | 714,757 | 1983 |
| Dr. Gary G. Li Ph.D. | Senior Vice President of Biology & Translational Medicine | 0 | N/A |
| Dr. Nicholas D. Smith Ph.D. | Senior Vice President of Chemistry Innovation | 0 | N/A |
| Mr. Jeff Woodley | General Counsel | 0 | N/A |
| Mr. Aron Marc Knickerbocker | Co-Founder | 0 | 1969 |
| Mr. Eric Bischoff | Senior Vice President of Development & Operations | 0 | N/A |
| Ms. Kimberly Ma M.S. | Senior Vice President of Clinical Operations | 0 | N/A |
| Mr. Abhi Bhat Ph.D. | Senior Vice President of Chemistry & Head of Discovery | 0 | N/A |
RayzeBio, Inc. develops radiopharmaceutical therapeutics (RPT) for the treatment of cancer. The company’s lead drug candidate is RYZ101, which is in phase 3 clinical trial for the treatment of gasteroenteropancreatic neuroendocrine tumors (GEP-NETs). It also develops RYZ801, a novel proprietary peptide that targets GPC3 for delivery of Ac225 for the treatment of hepatocellular carcinoma (HCC); RYZ811, a paired diagnostic imaging agent with the peptide binder, chelator, and Ga68 as the radioisotope; and a novel proprietary small molecule that targets CA9 for delivery of Ac225 for the treatment of ccRCC. The company was incorporated in 2020 and is based in San Diego, California.